Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Marinomed, Valneva, RBI (20/01/2025)

26.01.2025

Marinomed: Marinomed Biotech AG announced that the restructuring proceedings without self-administration opened on August 14^th, 2024, have been formally completed by resolution of the Korneuburg regional court on January 14^th, 2025. In December, the Company met all necessary prerequisites, including depositing the funds required for payment of the cash quota and the costs of the proceedings. With the formal end of the proceedings, administration by the insolvency administrator has also ended and the Management Board has regained control over the Company. “We are relieved that we were able to successfully complete the restructuring process. With the sale of the Carragelose business, we are well positioned to fulfill the restructuring plan. At the same time, our top priorities are now to develop a new strategy and to push ahead with the commercialization of our Marinosolv and Solv4U assets”, saya Andreas Grassauer, CEO of Marinomed.
Marinomed Biotech: weekly performance: -2.04%

Valneva: Austrian/French Valneva, a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ®, which showed a sustained 98.3% sero-response rate one-year after single vaccination. These results support and strengthen the pivotal data previously reported for adolescents (12 to 17 years old) which supported filing for potential label extension to this age group in the U.S., Europe, and Canada. Data from this trial are also expected to support licensure of IXCHIQ® in Brazil, which would be the first potential approval for use in endemic populations.
Valneva: weekly performance: 9.65%

RBI: In the legal proceedings initiated by Rasperia Trading Limited against STRABAG SE, STRABAG SE’s Austrian core shareholders and RBI’s (Raiffeisen Bank International) wholly owned Russian subsidiary AO Raiffeisenbank, a Russian court has rendered its verdict. The court has decided that STRABAG SE and its Austrian core shareholders are liable to pay EUR 2.044 billion to Rasperia and that the verdict can be enforced against AO Raiffeisenbank’s assets. AO Raiffeisenbank will appeal this verdict with suspensive effect. Subject to further developments in Russian courts, RBI Group will take legal actions in Austria, in full compliance with EU sanction law, to mitigate damages by seeking enforcement against Rasperia’s assets in Austria. AO Raiffeisenbank will book a provision for Q4/2024, in accordance with IFRS and Russian accounting standards.
RBI: weekly performance: 1.73%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (20/01/2025)


Partners









latest 21st Austria

21st Austria weekly - Marinomed, Valneva, RBI (20/01/2025)


26.01.2025, 2639 Zeichen



Marinomed: Marinomed Biotech AG announced that the restructuring proceedings without self-administration opened on August 14^th, 2024, have been formally completed by resolution of the Korneuburg regional court on January 14^th, 2025. In December, the Company met all necessary prerequisites, including depositing the funds required for payment of the cash quota and the costs of the proceedings. With the formal end of the proceedings, administration by the insolvency administrator has also ended and the Management Board has regained control over the Company. “We are relieved that we were able to successfully complete the restructuring process. With the sale of the Carragelose business, we are well positioned to fulfill the restructuring plan. At the same time, our top priorities are now to develop a new strategy and to push ahead with the commercialization of our Marinosolv and Solv4U assets”, saya Andreas Grassauer, CEO of Marinomed.
Marinomed Biotech: weekly performance: -2.04%

Valneva: Austrian/French Valneva, a specialty vaccine company, today reported further positive Phase 3 data in adolescents for its single-shot chikungunya virus (CHIKV) vaccine, IXCHIQ®, which showed a sustained 98.3% sero-response rate one-year after single vaccination. These results support and strengthen the pivotal data previously reported for adolescents (12 to 17 years old) which supported filing for potential label extension to this age group in the U.S., Europe, and Canada. Data from this trial are also expected to support licensure of IXCHIQ® in Brazil, which would be the first potential approval for use in endemic populations.
Valneva: weekly performance: 9.65%

RBI: In the legal proceedings initiated by Rasperia Trading Limited against STRABAG SE, STRABAG SE’s Austrian core shareholders and RBI’s (Raiffeisen Bank International) wholly owned Russian subsidiary AO Raiffeisenbank, a Russian court has rendered its verdict. The court has decided that STRABAG SE and its Austrian core shareholders are liable to pay EUR 2.044 billion to Rasperia and that the verdict can be enforced against AO Raiffeisenbank’s assets. AO Raiffeisenbank will appeal this verdict with suspensive effect. Subject to further developments in Russian courts, RBI Group will take legal actions in Austria, in full compliance with EU sanction law, to mitigate damages by seeking enforcement against Rasperia’s assets in Austria. AO Raiffeisenbank will book a provision for Q4/2024, in accordance with IFRS and Russian accounting standards.
RBI: weekly performance: 1.73%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (20/01/2025)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #841: Kickl hat es verkickelt, ATX erstmals seit 2022 über 4000, Strabag und Telekom sind Value Momentum Plus




 

Bildnachweis

Aktien auf dem Radar:Palfinger, RHI Magnesita, RBI, Warimpex, Pierer Mobility, Zumtobel, OMV, Telekom Austria, Österreichische Post, ATX, ATX Prime, ATX TR, Bawag, Andritz, Erste Group, Strabag, Uniqa, Wienerberger, CA Immo, BTV AG, EuroTeleSites AG, UBM, Porr, Flughafen Wien, Oberbank AG Stamm, Agrana, Amag, EVN, Rosenbauer, SBO, VIG.


Random Partner

Agrana
Die Agrana Beteiligungs-AG ist ein Nahrungsmittel-Konzern mit Sitz in Wien. Agrana erzeugt Zucker, Stärke, sogenannte Fruchtzubereitungen und Fruchtsaftkonzentrate sowie Bioethanol. Das Unternehmen veredelt landwirtschaftliche Rohstoffe zu vielseitigen industriellen Produkten und beliefert sowohl lokale Produzenten als auch internationale Konzerne, speziell die Nahrungsmittelindustrie.

>> Besuchen Sie 68 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten